1. Home
  2. CXM vs URGN Comparison

CXM vs URGN Comparison

Compare CXM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

HOLD

Current Price

$5.63

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$27.89

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXM
URGN
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
CXM
URGN
Price
$5.63
$27.89
Analyst Decision
Hold
Strong Buy
Analyst Count
8
7
Target Price
$8.28
$29.29
AVG Volume (30 Days)
3.0M
816.1K
Earning Date
06-03-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$857,200,000.00
$1,128,000.00
Revenue This Year
$2.52
$129.09
Revenue Next Year
$4.94
$70.96
P/E Ratio
$59.72
N/A
Revenue Growth
7.64
N/A
52 Week Low
$4.72
$4.36
52 Week High
$9.40
$32.37

Technical Indicators

Market Signals
Indicator
CXM
URGN
Relative Strength Index (RSI) 60.84 53.99
Support Level $5.19 $27.34
Resistance Level $6.16 $30.00
Average True Range (ATR) 0.22 1.64
MACD 0.06 -0.35
Stochastic Oscillator 95.78 13.12

Price Performance

Historical Comparison
CXM
URGN

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: